Market Overview

Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Share:
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

  • Leerink recently hosted 24 biopharmaceutical companies at a roundtable event.
  • Of the 24 companies, Leerink now rates 20 of them as Outperform.
  • Many of these 20 companies have strong potential catalysts coming relatively soon.
  • Leerink Partners recently hosted a Rare Disease Roundtable that included fireside chats with 24 biopharmaceutical companies. Following the event, analyst Joseph Schwartz released a report that included a list of 20 Outperform-rated names that attended the roundtable.

    Here’s a list of some of the potential catalysts Schwartz sees for these companies.

    Highlighted Stocks And Catalysts

  • Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR): The company is guiding conservatively for Juxtapid sales.
  • Agios Pharmaceuticals Inc (NASDAQ: AGIO): The company is seeing clinical benefit in solid tumor indications.
  • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY): The company reports solid enrollment in APOLLO Ph. III trial and positive OLE Phase II data.
  • Related Link: Morgan Stanley Sees Drug Pricing Still An Overhang For These Names

  • Ascendis Pharma A/S (NASDAQ: ASND): The company is ramping up manufacturing ahead of Ph. III trial in growth deficiency patients.
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN): The company has a scheduled PDUFA date of December 27.
  • Cidara Therapeutics Inc (NASDAQ: CDTX): The company is executing well on CD101 development.
  • Dicerna Pharmaceuticals Inc (NASDAQ: DRNA): A decision on the fate of DCR-MYC is expected by the end of 2016.
  • Other Names

    In addition to the specific names mentioned above, Leerink also sees potential upcoming catalysts for the following Outperform-rated names in the space:

    • Auris Medical Holding AG (NASDAQ: EARS)
    • Epizyme Inc (NASDAQ: EPZM)
    • Fate Therapeutics Inc (NASDAQ: FATE)
    • Amicus Therapeutics, Inc. (NASDAQ: FOLD)
    • Insmed Incorporated (NASDAQ: INSM)
    • ProQR Therapeutics NV (NASDAQ: PRQR)
    • Uniqure NV (NASDAQ: QURE)
    • Raptor Pharmaceutical Corp. (NASDAQ: RPTP)
    • Retrophin Inc (NASDAQ: RTRX)
    • SAGE Therapeutics Inc (NASDAQ: SAGE)
    • Acceleron Pharma Inc (NASDAQ: XLRN)
    • Zafgen Inc (NASDAQ: ZFGN)
    • Zogenix, Inc. (NASDAQ: ZGNX)

    Disclosure: The author holds no position in the stocks mentioned.

    Image Credit: Public Domain

    Posted-In: BiopharmaceuticalAnalyst Color Biotech Long Ideas Top Stories Analyst Ratings Trading Ideas General Best of Benzinga

     

    Related Articles (AEGR + AGIO)

    View Comments and Join the Discussion!

    Exxon Mobil Follow Crudes Oil Higher But Finds Resistance

    Why SprucePoint Is Bearish On Caesarstone Stock